MOLCURE today announced the appointment of leading biotechnology executive-scientist Dr. Han Lim, M.B.B.S., Ph.D. as strategic advisor.
Dr. Lim is currently the Chief Business Officer at DeepCure, Inc., and was formerly the Chief Business Officer at Atomwise Inc. He has also served on a number of boards and steering committees, and is a frequent speaker and panelist on artificial intelligence (AI) enabled drug discovery. Dr. Lim has broad operational and management experience in growing AI biotechnology companies. He is an internationally recognized leader in business development, having formed AI drug discovery partnerships with pharmaceutical and biotechnology companies, launched joint venture companies, and established collaborative research projects with more than 500 universities. Dr. Lim is also an experienced scientist and former faculty member at the University of California Berkeley. He has published innovative research on systems biology, bioengineering, RNA, and genetics in high profile journals.
“We are delighted to welcome Dr. Han Lim as our advisor,” said Dr. Ryu Ogawa, CEO of MOLCURE. “MOLCURE is well positioned to become a leader in biologics discovery, and we’re excited to have the benefit of Han’s advice on this journey. His track record of success in business and research, innovative and creative thinking, and deep knowledge of AI drug discovery will provide our team with valuable perspectives, and helpful guidance.”
“I’m excited about MOLCURE’s mission to transform the discovery of biologics for challenging targets, and honored to have the opportunity to support MOLCURE in achieving its goals,” said Dr. Lim. “MOLCURE is using its proprietary platform technologies to generate high quality experimental data at scale to unlock the full potential of AI for discovering new therapeutics.”
About MOLCURE Inc.
MOLCURE was founded in 2013 with a mission to build the best platform for biologics discovery in the world. Today, its platform integrates AI with evolutionary molecular engineering, next-generation sequencing, laboratory automation technologies, and a proprietary database containing more than one billion molecular entries. These capabilities enable the delivery of diverse, high affinity, specific, and functional antibodies and peptides for researchers. MOLCURE is partnering with innovative companies to discover therapeutics with the potential to benefit patients around the world.
<Corporate Information>
Company Name: MOLCURE Inc.
CEO: Ryu Ogawa
Head Office Address: AIRBIC A07, 7-7 Shinkawasaki, Saiwai-ku, Kawasaki City, Kanagawa, Japan
https://molcure.com
<For media and service inquiries>
Email: contact[@]molcure.io
